UBS Keeps Their Hold Rating on Argenx Se (ARGX)
Goldman Sachs Adjusts Price Target on Mettler-Toledo International to $1,300 From $1,150, Maintains Neutral Rating
Gilead Sciences Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)
JPMorgan Chase Raises Price Target on Alnylam Pharmaceuticals to $248 From $160
Mettler-Toledo Intl Analyst Ratings
Evercore ISI Adjusts Price Target on Mettler-Toledo International to $1,390 From $1,375, Maintains In-line Rating
Buy Rating Affirmed for Argenx Se on Strong Vyvgart Uptake and Promising Revenue Projections
Alnylam Pharmaceuticals Analyst Ratings
Gilead Sciences Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $150 Price Target
Wedbush Sticks to Their Buy Rating for Argenx Se (ARGX)
Argenx Analyst Ratings
Gilead Sciences (GILD) Receives a Hold From RBC Capital
IQVIA Hldgs Analyst Ratings
Amgen Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Moderna Analyst Ratings